Development of tools for customizing and monitoring of acoustic treatment for COVID‑19 patients
Dymedso, a Canadian-based medical device SME specialized in pulmonary disease therapeutic and treatment equipment is a patented and award-winning pioneer in using sound (acoustics) to treat patients requiring airway clearance such as Cystic Fibrosis COPD and the coronavirus family, SARS, MERS and naturally COVID-19. The company’s Frequencer® device has FDA, Health Canada, European CE, and UL (North America, Europe, Australia, and New Zealand) approvals and has been used in hospitals since 2010 with an established base of more than 650 devices in operations around the globe.
Dymedso continues to explore the ways to improve its product to treat a wider range of patients requiring the airway. The goal of Dymedso (Richard Boudreault, CEO) and the University of Waterloo (Yuri Leonenko, PI) partnership is to customize of use of existent company devices for effective treatment of COVID‑19 patients.
Potential outcomes of the proposed research are the development of new tools (devices and protocols) which allow quantitatively: i) determine the optimal customized treatment for each particular patient; ii) real-time monitoring of the effectiveness of the acoustic treatment allowing adjustments if needed. It will dramatically increase the effectiveness and variety of treatment protocols depending on patient conditions, for example at the early phase of COVID-19, (the dry cough), or at the wet pneumonic phase of the disease.
